Loading
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Latest quote
¥111
−¥5.00 · -4.31%
Regular session · JST · Market data may be delayed.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Day range
Current ¥111
52-week range
Current ¥111
Regular session · JST · Market data may be delayed.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.
Day range
Current ¥111
52-week range
Current ¥111
Operating income
Net income
| Metric (JPY) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 300M JPY |
| Cost of goods sold | 1.44M JPY | 1.59M JPY | 1.51M JPY | 1.63M JPY | — |
| Gross profit | −1.44M JPY | −1.59M JPY | −1.51M JPY | −1.63M JPY | 300M JPY |
| Research and development | 1.33B JPY | 1.44B JPY | 1.12B JPY | 1.01B JPY | 940.79M JPY |
| Selling, general, and administrative | 273.97M JPY | 209.6M JPY | 227.07M JPY | 258.98M JPY | 284.97M JPY |
| Operating expenses | 1.6B JPY | 1.71B JPY | 1.4B JPY | 1.31B JPY | 1.26B JPY |
| Interest income | 921K JPY | 337K JPY | 14K JPY | 13K JPY | 70K JPY |
| Depreciation and amortization | 1.44M JPY | 1.59M JPY | 1.51M JPY | 1.63M JPY | 1.67M JPY |
| Operating income | −1.61B JPY | −1.71B JPY | −1.4B JPY | −1.32B JPY | −961.46M JPY |
| Net income | −1.63B JPY | −1.72B JPY | −1.43B JPY | −1.33B JPY | −967.3M JPY |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
